Welcome to our dedicated page for AC Immune SA news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune SA stock.
AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, committed to pioneering precision medicine for neurodegenerative diseases. The company specializes in designing, discovering, and developing innovative therapeutic and diagnostic products aimed at preventing and modifying diseases caused by misfolded proteins. Utilizing its two proprietary technology platforms, SupraAntigen® and Morphomer®, AC Immune develops a broad spectrum of antibodies, small molecules, and vaccines targeting conditions such as Alzheimer’s disease (AD), Parkinson’s disease, and NeuroOrphan indications.
With a robust pipeline consisting of sixteen therapeutic and diagnostic programs, AC Immune currently has six product candidates in clinical trials, including five in Phase 2 and one in Phase 3. The most advanced candidate, Crenezumab, is a humanized anti-amyloid-β monoclonal antibody in Phase 3 trials aimed at treating Alzheimer’s disease. Other notable candidates include ACI-24.060, a promising anti-Abeta active immunotherapy for AD and Down syndrome, which has received FDA Fast Track Designation, and ACI-35.030, an anti-pTau active immunotherapy in Phase 2b trials for preclinical AD conducted by Janssen Pharmaceuticals.
Beyond its rich pipeline, AC Immune is known for its strategic partnerships with leading global pharmaceutical companies such as Genentech (a Roche Group member), Eli Lilly and Company, and Takeda. These collaborations have resulted in significant non-dilutive funding and milestone payments totaling over $4.5 billion.
AC Immune recently secured an exclusive option and license agreement with Takeda for its ACI-24.060 product, potentially worth $2.1 billion, and completed a $50 million equity financing to support its operations into 2026. The company's focused efforts on precision prevention are reinforced by its ongoing Phase 2 trials and collaborations aimed at leveraging advanced diagnostic techniques like PET imaging and novel therapeutic approaches for early and effective intervention in neurodegenerative diseases.
AC Immune (NASDAQ: ACIU), a leading biopharmaceutical company focused on neurodegenerative diseases, announced its participation in the Jefferies Virtual London Healthcare Conference on November 18, 2020. CEO Prof. Andrea Pfeifer will discuss the company’s strategies for 2021, particularly its candidates targeting TAR DNA-binding protein 43 (TDP-43), which is critical in conditions like Alzheimer’s and amyotrophic lateral sclerosis (ALS). The presentation aims to highlight their innovative approach to precision medicine in treating these diseases.
AC Immune SA has entered a strategic partnership with WuXi Biologics to advance its TDP-43 antibody into clinical development for NeuroOrphan indications. This agreement leverages AC Immune's drug discovery platforms and WuXi's manufacturing capabilities to address the significant unmet medical needs related to TDP-43-related neurodegenerative diseases. The collaboration aims to expedite the drug development process, with AC Immune retaining all intellectual property rights. This partnership highlights the company's growth and commitment to bringing innovative treatments to market.
AC Immune (NASDAQ: ACIU) has secured a €1.45M grant from the EU's Joint Programme – Neurodegenerative Disease Research (JPND). This funding will support the development of the first-in-class TDP-43 PET tracer in collaboration with the JPND ImageTDP-43 consortium, aimed at detecting neurodegenerative diseases including ALS and FTLD-TDP. The company emphasizes its innovative Morphomer™ platform's role in advancing precision medicine, as highlighted by CEO Prof. Andrea Pfeifer. The TDP-43 PET tracer shows strong binding to pathological aggregates, enhancing diagnostics and potential treatments for Alzheimer’s disease.
AC Immune (NASDAQ: ACIU) announced its participation in the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020. CEO Prof. Andrea Pfeifer will present the company’s advanced anti-Tau clinical pipeline, which includes an antibody, a small molecule inhibitor, and a vaccine targeting neurodegenerative diseases. The presentation will highlight recent results from their Tau PET imaging agent, PI-2620, which may aid in earlier diagnosis of progressive supranuclear palsy (PSP). Four clinical-stage assets are in development.
AC Immune SA (NASDAQ: ACIU) announced the start of investigational new drug (IND)-enabling studies for its first-in-class anti-TDP-43 antibody, which is the only antibody reported to have in vivo activity against TDP-43 neuropathology. This antibody targets various neurodegenerative conditions, including ALS and FTLD-TDP, associated with significant market potential. The initiative follows several key achievements in the company’s pipeline, which utilizes the proprietary SupraAntigen™ and Morphomer™ platforms. CEO Andrea Pfeifer emphasized the importance of this milestone in addressing unmet needs in neurodegenerative diseases.
AC Immune (NASDAQ: ACIU) presented innovative data for its next-generation alpha-synuclein PET tracer at the Alzheimer’s Association International Conference (AAIC) on July 28, 2020. The preclinical results highlight improved contrast and specificity for diagnosing Parkinson’s disease, meeting a significant clinical need. The company’s Morphomer™ platform is key to developing these diagnostics. ACI-12589 shows promise as a first-class imaging agent, advancing the company's therapeutic and diagnostic strategies for neurodegenerative diseases, particularly alpha-synucleinopathies.
AC Immune (NASDAQ: ACIU) announced that it will deliver two oral presentations at the Alzheimer’s Association International Conference (AAIC), running virtually from July 27 to 31, 2020. The presentations will cover the company's advancements in the alpha-synuclein PET tracer program and the Phase 1b trial of the ACI-24 anti-Abeta vaccine in Down syndrome. These presentations highlight AC Immune’s innovative pipeline targeting neurodegenerative diseases and confirm its commitment to pioneering diversified approaches in Alzheimer’s treatment.
AC Immune SA (NASDAQ: ACIU) has advanced to the second highest dosing group in its Phase 1b/2a clinical trial for ACI-35.030, an investigational vaccine targeting Alzheimer’s disease. This decision follows promising interim results showing safety, tolerability, and immunogenicity. ACI-35.030 aims to generate an antibody response against pathological phospho-Tau proteins, potentially mitigating Tau pathology. The trial will assess safety, tolerability, and clinical outcomes over 48 weeks. This vaccine builds on previous successes and is developed in collaboration with Janssen Pharmaceuticals.
AC Immune SA (NASDAQ: ACIU) and Life Molecular Imaging announced the publication of clinical results for the Tau-PET tracer PI-2620, showing its potential in diagnosing progressive supranuclear palsy (PSP). Published in JAMA Neurology, the study indicates that PI-2620 allows improved detection of Tau protein deposits associated with PSP, potentially leading to earlier and more accurate diagnoses. The tracer has already exhibited effectiveness in detecting Tau pathology in Alzheimer's disease. This development enhances the diagnostic capabilities for neurodegenerative disorders and could influence future therapeutic interventions.
FAQ
What is the current stock price of AC Immune SA (ACIU)?
What is the market cap of AC Immune SA (ACIU)?
What is AC Immune's primary focus?
What are AC Immune's most advanced product candidates?
What technology platforms does AC Immune use?
Who are AC Immune's strategic partners?
What is the significance of the recent agreement with Takeda?
How is AC Immune funded?
What is AC Immune’s financial outlook?
What ongoing clinical trials is AC Immune conducting?
What recent milestones has AC Immune achieved?
How does AC Immune contribute to the field of neurodegenerative disease research?
